Please assess the completion status of the following clinical trial:

Trial Title: Alpers Huttenlocher Natural History Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All individuals of any age with confirmed Alpers Huttenlocher Syndrome (AHS) or siblings of confirmed AHS patients are eligible to participate. AHS requires the presence of polymerase gamma 1 (POLG) pathological mutations, either homozygous or compound heterozygote mutations, and the presence of epilepsy and either, developmental regression or hepatopathy. If POLG mutations are not demonstrated, AHS requires the presence of refractory seizures, developmental regression, and hepatopathy as well as two or more other clinical and laboratory findings including elevated cerebrospinal fluid (CSF) protein, neuroimaging showing lactate peaks, reduced N-acetyl aspartate with hyperintensities on T2/FLAIR in the thalamus and posterior head regions, optic atrophy/cortical blindness, quantitative mtDNA reduction (\>30% ) in muscle and/or liver, non-specific electron transport chain (ETC) enzyme deficiencies.~* All patients must agree to participate in the North American Mitochondrial Disease Consortium (NAMDC) Clinical Registry~Exclusion Criteria:~* Patient does not have confirmed AHS and is not the sibling of a patient with confirmed AHS~* Not willing to participate in the NAMDC clinical Registry

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients with Alpers-Huttenlocher (Type: None): Patients confirmed to have Alpers Huttenlocher Syndrome
- Siblings (Type: None): Siblings of patients with Alpers Huttenlocher Syndrome

Based on this trial design, predict the completion outcome and termination type (if applicable).